PLX51107
- Generic Name
- PLX51107
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C26H22N4O3
- CAS Number
- 1627929-55-8
- Unique Ingredient Identifier
- W758F1L9ND
- Background
PLX51107 is a potent and selective inhibitor of the bromodomain and extraterminal (BET) protein family. PLX51107 is under investigation in clinical trial NCT04022785 (PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome).
- Associated Conditions
- -
- Associated Therapies
- -
Novel BET Inhibitor PLX51107 for Steroid-Refractory Acute GVHD
- Conditions
- Interventions
- First Posted Date
- 2021-06-02
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Hannah Choe, MD
- Target Recruit Count
- 2
- Registration Number
- NCT04910152
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
- First Posted Date
- 2019-07-17
- Last Posted Date
- 2022-10-31
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 43
- Registration Number
- NCT04022785
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Study of PLX51107 in Advanced Malignancies
- Conditions
- Interventions
- First Posted Date
- 2016-02-17
- Last Posted Date
- 2018-12-24
- Lead Sponsor
- Plexxikon
- Target Recruit Count
- 50
- Registration Number
- NCT02683395
- Locations
- 🇺🇸
The Ohio State University Stephanie Spielman Comprehensive Breast Center, Columbus, Ohio, United States
🇺🇸Columbia University Medical Center, New York, New York, United States
🇺🇸South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.